Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301779 · ClinicalTrials.gov registry record · Phase 2
Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
A Phase 2 study of Whole Blood Donation and Leukoreduction, sponsored by Hemanext.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT03301779: Completed Phase 2 study of Whole Blood Donation and Leukoreduction, sponsored by Hemanext.
NCT03301779 is a Phase 2 study of Whole Blood Donation and Leukoreduction that has completed, run by Hemanext. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03301779, a Phase 2 study of Whole Blood Donation and Leukoreduction, has completed, sponsored by Hemanext.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary goal of Hemanext. is to improve red cell storage through novel storage methods. Based on our review of the pertinent literature, there is substantial evidence suggesting that prolonged exposure to oxygen during storage results in oxidative damage to the red blood cells leading to decreased therapeutic potential. Therefore, removal of oxygen from red blood cell products prior to storage has potential to preserve the cells in a more physiologically relevant state. Currently, Hemanext has focused on the design and development of a dual compartment bag system designated as the Hemanext Red Blood Cell Processing System. After standard processing of donated whole blood units into leukoreduced packed red blood cells (LR-RBCs) with the appropriate additive solutions, the LR-RBCs would then be placed in the oxygen reduction bag (ORB) which allows for the rapid diffusion of oxygen out of the blood, through a sterile, oxygen-permeable membrane, and into iron-based oxygen sorbents. After processing, the blood is transferred again from the ORB into the Hemanext storage bag (HSB) which will preserve the anaerobic state of the LR-RBC product for the duration of cold storage. Hemanext has conducted preliminary storage tests to ascertain the effects of anaerobic storage on overall blood health in various storage solutions. The research team has focused primarily on percent hemolysis, which is mandated by the FDA to remain below 1% for the duration of storage, as well as ATP and 2,3-DPG levels.
Primary Outcome
Percentage of packed Red Blood Cell units with hemolysis at day 42 of storage.
Conditions Studied
Interventions
- DEVICE Hemanext Red Blood Cell Processing System
Study Locations (3)
Ohio
- Hoxworth Blood Center, University of Cincinnati - Cincinnati
Virginia
- American Red Cross Mid-Atlantic Research Facility - Norfolk
Wisconsin
- Blood Center of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2019-03-06 |
| Phase | Phase 2 |
What the finished NCT03301779 record still lists
NCT03301779 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Whole Blood Donation and Leukoreduction appearing as the primary indexed condition, and to 1 intervention - of which Hemanext Red Blood Cell Processing System is the first listed.
NCT03301779 reports a single indexed study location in Ohio, Virginia, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03301779 about?
NCT03301779 is a clinical study titled "Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial". The primary goal of Hemanext. is to improve red cell storage through novel storage methods. Based on our review of the pertinent literature, there is substantial evidence suggesting that prolonged exposure to oxygen during storage results in oxidative damage to the red blood cells leading to decreas...
What is the current status of trial NCT03301779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-11-27. Estimated completion is 2019-03-06.
What conditions does trial NCT03301779 study?
This clinical trial studies the following conditions: Whole Blood Donation and Leukoreduction.
What interventions are being tested in trial NCT03301779?
The interventions under investigation include: Hemanext Red Blood Cell Processing System (DEVICE).
Who is sponsoring clinical trial NCT03301779?
This trial is sponsored by Hemanext, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03301779 being conducted?
This trial has 3 study locations across Ohio, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03301779's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI